Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Refusal Reversal: Alkermes Review Back On Track, But Could Still Be Bumpy

Executive Summary

US FDA accepts Alkermes' NDA for depression drug after issuing refuse-to-file letter just two weeks ago; unusual move falls outside agency's guidance on RTFs because no changes were made to submission and it wasn't filed over protest.


Related Content

Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
Alkermes Advisory Committee Hears More About Refuse-To-File Letter Thanks To Industry Rep
Alkermes' Depression Drug Likely Needs Another Trial After Crushing US Advisory Cmte. Vote
Alkermes Depression Drug Faces Tough Questions At US FDA Advisory Committee
Can US FDA's Talk Therapy Cure What Ails Mental Health R&D?
Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
Rescinding A Refuse-To-File: A Precedent Of Sorts
Keeping Track Of Bad News: Alkermes' Depression Candidate Gets Refuse To File; Teva/Celltrion Biosimilars Land CRLs
Refuse-to-File Turns 25: New Guidance Changes In Style, But Not Substance
FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts